Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

If you’ve ever had to pause a promising experiment while waiting on titer results, you’re not alone. In many labs, samples come off the bioreactor only to sit in line for ELISA or HPLC - and decisions ...

From stable transfection to bioreactor scale-up, cell line development is a complex and resource-intensive process. Researchers face challenges in achieving monoclonality, optimizing media, managing ...

In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory expectations. Yet one factor often determines long-term success more than any ...

To achieve this progress, biologic production has had to reinvent itself. Although biologics were once sourced directly from donated blood plasma or cells, the backbone of this process is now a ...

To test the accuracy of the Octet ® assay, Fc-fusion protein was spiked into CCM and HCP matrices at known concentrations in ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...

WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO), announced the launch of WuXia293Stable, a new platform designed for the development and ...

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...